FleuryBSP:FLRY3 +1.04%91 FCF Margin % is 9.17% as of Mar. 2026, which is 42% below its 10-year median of 15.74. GuruFocus rates BSP:FLRY3 with a GF Score™ of 91/100 and a GF Value™ of R$17.41 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 204 Medical Diagnostics & Research companies, Fleury ranks better than 87.25% on this metric.
FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Fleury's Free Cash Flow for the
three
months ended in Mar. 2026 was R$204 Mil. Fleury's Revenue for the
three
months ended in Mar. 2026 was R$2,223 Mil. Therefore, Fleury's FCF Margin % for the quarter that ended in Mar. 2026 was 9.17%.
The historical rank and industry rank for Fleury's FCF Margin % or its related term are showing as below:
BSP:FLRY3'
s FCF Margin % Range Over the Past 10 Years
Min: 9.82 Med: 15.74 Max: 19.63
Current: 18.55
During the past 13 years, the highest FCF Margin % of Fleury was 19.63%. The lowest was 9.82%. And the median was 15.74%.
BSP:FLRY3's FCF Margin % is ranked better than 87.25% of 204
companies
in the Medical Diagnostics & Research industry
Industry Median: -1.845
vs BSP:FLRY3: 18.55
Fleury FCF Margin % Related Terms
Fleury FCF Margin % Historical Data
* Premium members only.
The historical data trend for Fleury's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BSP:FLRY3 vs TMO, DHR, IDXX: FCF Margin % Comparison
For the Diagnostics & Research subindustry, Fleury's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Fleury FCF Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Fleury's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Fleury's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Fleury (BSP:FLRY3) has a FCF Margin % of 9.17% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Fleury and its competitors. This is 42% below median its historical median of 15.74. Over the past decade, Fleury's FCF Margin % has ranged from 9.82 to 19.63. According to the industry distribution chart, Fleury ranks #26 out of 204 companies in the Medical Diagnostics & Research industry, placing it in the top 12.7%.
Is Fleury's FCF Margin % too high?
Fleury's current FCF Margin % of 9.17% is 42% below median its 10-year median of 15.74. Over the past 10 years, this metric has ranged from a low of 9.82 to a high of 19.63. Based on the distribution chart, Fleury ranks #26 out of 204 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Fleury has a GF Score™ of 91/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Fleury's FCF Margin % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Fleury ranks #26 out of 204 companies for FCF Margin %. This places Fleury in the top 13% of its industry — outperforming the majority of peers. Historically, Fleury's own FCF Margin % has ranged from 9.82 to 19.63 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Medical Diagnostics & Research company?
A good FCF Margin % depends on the Medical Diagnostics & Research industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Fleury and its competitors. Fleury's current FCF Margin % is 9.17%, which is 42% below median its own 10-year median of 15.74. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fleury stock overvalued right now?
Based on GuruFocus' analysis, Fleury (BSP:FLRY3) is currently considered Modestly Undervalued. The stock's GF Value™ is R$17.41, compared to a current price of R$15.61 — trading 10.3% below its estimated fair value. The current FCF Margin % is 9.17%, which is 42% below median its 10-year median of 15.74. Fleury's overall GF Score™ is 91/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Fleury (BSP:FLRY3), the current FCF Margin % is 9.17% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Fleury (BSP:FLRY3) Overvalued in 2026?
Based on GuruFocus' analysis, Fleury stock appears to be undervalued.
The current stock price of R$15.61 is trading 10.3% below its estimated GF Value™ of R$17.41.
GuruFocus considers Fleury to be Modestly Undervalued.
Key valuation signals for BSP:FLRY3:
FCF Margin %: 9.17% (42% below median its 10-year median of 15.74)
GF Value™: R$17.41 vs. price of R$15.61 (10.3% below fair value)
No single metric tells the full story. See the BSP:FLRY3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Fleury SA is engaged in the provision of medical services in the diagnostic, laboratory support (Lab-to-Lab), infusions, clinical analysis, health management, medical care, orthopedics and ophthalmology, fertility, infusion areas and toxicological exams, among others. The company offers diagnostic medicine through physical service units and mobile diagnostic services for consumers. It also provides diagnostic support services to laboratories and hospitals. In addition, the company operates clinics and services in areas such as infusion therapy, orthopedics, ophthalmology, reproductive medicine, and oncology. It has two reportable business segments: Diagnostic Medicine and Integrated Medicine. The maximum revenue is generated from the Diagnostic Medicine Segment.
91GF Score
Get the complete analysis for BSP:FLRY3
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BSP:FLRY3 has been successfully added to your 
